APAC Parkinson’s Disease Treatment Market Analysis


  • Type: Common Disease Area
  • Published : January 2022
  • Region: APAC
  • Country: Other
  • Report ID : 5029

  • Format: PPT, PDF

APAC Parkinson’s Disease Treatment Market Analysis: Segmented by Drug Class, Distribution Channel, Patient Care Setting, and Country- Growth, Market Size, Future Prospects & Competitive Analysis, 2020 – 2028


Report Description of the APAC Parkinson’s Disease Treatment Market Analysis

Research Scope and Assumption

  • The report provides the market value for the base year 2020 and a yearly forecast up to 2028 in terms of revenue (USD billion)
  • The key industry dynamics, regulatory scenario, reimbursement scenario, major market trends, and drug markets are evaluated to understand their impacts on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis
  • We have used the combination of top-down and bottom-up approach for market sizing, analyzing key regional markets, dynamics, and trends for various solutions, services, and end uses
  • All market estimates and forecasts have been validated through primary interviews with the Key Industry Players (KIPs) and secondary analysis
  • Inflation has not been accounted for in order to estimate and forecast the market
  • Numbers may not add up due to rounding off

Reason to buy the report:

  • Facilitate decision-making based on strong current and forecast data for APAC Parkinson’s Disease Treatment  Market  Analysis
  • Develop strategies based on the latest regulatory framework
  • Strategically analyze micro-markets with respect to individual growth trends, future prospects, and their contribution to the market
  • Analyze competitive developments such as expansions, investments, mergers & acquisitions, new product developments, and research & developments in the APAC Parkinson’s Disease Treatment  Market  Analysis
  • Analyze the opportunities in the market for stakeholders and draw a competitive landscape for market leaders
  • To strategically profile key players and comprehensively analyze their market shares and core competencies
  • We have technically sound team which do a deep dive research and also provide strategy based consulting analysis

APAC Parkinson’s Disease Treatment Market Analysis Executive Summary

Parkinson’s is a type of movement disorder that affects the ability to perform common daily activities. It is a chronic and progressive disease. It is characterized by its most common motor related symptoms like tremors (a form of rhythmic shaking), stiffness or rigidity of muscles, and slowness of movement (called bradykinesia). Also, non-motor symptoms including sleep problems, constipation, anxiety, depression, fatigue, and others.

Market Size and Key Findings

The APAC Parkinson’s Disease Treatment Market Analysis size stood at around USD 1.04 billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of 6.79% during the forecast period.

The size of the Asia Pacific Parkinson’s Disease Treatment Market was worth USD 1.04 billion in 2020 and estimated to be growing at a CAGR of 6.79%, to reach USD xx billion by 2028.

Market Dynamics

Market Growth Drivers Analysis

An increasing account of the geriatric population and continuously growing patient base are likely to boost the demand for Parkinson’s treatments and expand growth opportunities for the stakeholders in the APAC market. The continually increasing number of aging people and increased prevalence of Parkinson’s disease are the major factors that are boosting the demand of the Asia Pacific Parkinson’s disease treatment market. The development of innovative and novel treatment methods and increasing popularity for minimally invasive surgeries among the people are propelling the growth of the Asia Pacific Parkinson’s disease treatment market. The increasing awareness among the people regarding healthcare is also boosting up the growth rate of Parkinson’s disease treatment market in the Asia Pacific.

Market Restraints

Stringent regulatory rules and policies are the significant challenges to the growth rate of Parkinson’s disease treatment market in this area. Unfavorable reimbursement policies are limiting the growth of Asia Pacific Parkinson’s disease treatment market. The availability of alternative treatments is a major challenge for the growth of the Asia Pacific Parkinson’s disease treatment market and is expected to restrain the market during the forecast period.

COVID-19 impact on “APAC Parkinson’s Disease Treatment Market”

The COVID-19 pandemic is associated with wide-ranging effects on people with PD, and certain groups may be at particular risk. The COVID-19 pandemic has impacted the management of patients with neurological disorders. In general, replacing outpatient care with telemedicine, postponing surgery, including deep brain stimulation, and avoiding nonemergency hospitalizations have been recommended for patients with PD and other movement disorders during the COVID-19 pandemic

Competitive Landscape

Key Players

Leading companies dominating the APAC Parkinson’s Disease Treatment Market profiled in this report are Teva (Israel), Novartis AG (Switzerland), GSK (UK), AbbVie (US), Merck (US). Boehringer Ingelherm (Germany), Impax Laboratories (US), Lundbeck (Denmark), Sun Pharma (India), Wockhardt (India), UCB (Belgium), Valeant Pharmaceuticals (Canada), and Acadia (US).

Products in Pipeline

In February 2018, Adamas Pharmaceuticals, Inc. announced subgroup analyses of Parkinson’s disease patients taking amantadine immediate release (IR) who are still experiencing dyskinesia and enrolled into EASE LID 2, the long-term. Ongoing phase 3 open label study of GOCOVRI™ (amantadine) extended release capsules results show that there is around 35% improvements in motor applications. The safety and tolerability profile of this patient was observed to be consistent without any adverse effects. Additionally, most of the major players have a robust drug pipeline for the treatment of Parkinson’s disease.

According to Clinicaltrials, to treat Parkinson’s disease NLY01 is in Phase 2 clinical trials. The Phase 2 study is designed to access the safety, tolerability, and efficacy of NLY01 for early untreated Parkinson’s disease (PD). Evidence suggests that NLY01, a pegylated form of exenatide can prove beneficial in Parkinson’s disease and is being developed as a potential treatment for neurodegenerative disorders. Actual start date of the study was February 2020 and estimated completion date is August 2022.

Notable Recent Deals

  • In June 2016, ACADIA Pharmaceuticals announced approval of NUPLAZID™ (pimavanserin) by the FDA. This is the first drug used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.
  • In 2016, Sun Pharmaceutical Industries Ltd. (India) entered distribution agreement with Mitsubishi Tanabe Pharma Corporation (Japan) to distribute 14 prescription brands that include Parkinson’s disease drug Parlodel in Japan.
  • In August 2020, Biogen announced collaboration with Denali on LRRK2 program for Parkinson’s disease and certain TV platform enabled programs for neurodegenerative disease.

Healthcare Policies and Regulatory Landscape

Policy changes and Reimbursement scenario

Increasing focus on the R&D activities by the private and public organizations for developing novel and innovative treatment methods owing to immense advancements in healthcare are expected to be creating more growth opportunities for the market over the forecast period. Since 1978, the development of clinical research and bedside work of PD in China is fascinating. The amount of publications increases from zero to the second place in the world. The bedside work develops from personal experience to standardized diagnosis and treatment. By 2030, there will be a half of worldwide PD patients in China. There are more and more doctors paying attention to PD. Clinical researches provide important data for amending health policies of PD, such as cost for DBS could be reimbursed in health insurance for PD. However, several problems remain to be solved. Huge burden of tertiary hospital doctors, lack of experienced doctors in primary and secondary hospitals in PD, and the lack of dual referral system in tertiary network are the current major issues. Lack of standardized PD database is another issue. Chinese expert consensus on clinical database construction of PD and movement disorders brought up by CMDS has been published recently to standardize the construction on clinical database. Due to uneven disease education level of PD, visiting rate and treatment rate are low and imbalanced among different areas. High quality clinical research articles are few currently. Noted, most articles are focused in Han ethnicity. The 55 minor ethnicities are seldom covered in most researches. There are slightly different beliefs and lifestyles of these minor ethnicities. But few researches focused on minor ethnicities. More researches focused on PD in minor ethnicities are warranted.

1. Report Description of the APAC Parkinson’s Disease Treatment Market Analysis
1.1 Research Scope and Assumption
1.2 Objective of the study
1.3 Research Methodology
1.4 Reason to buy the report
2. APAC Parkinson’s Disease Treatment Market Analysis Executive Summary
2.1 APAC Parkinson’s Disease Treatment Market Analysis – Industry Snapshot & key buying criteria, 2020-2028
2.2 Market Size, Growth Prospects and Key findings
3. Market Dynamics of APAC Parkinson’s Disease Treatment Market Analysis
3.1 Market Growth Drivers Analysis
3.1.1 Increase in the prevalence of Parkinson’s disease
3.1.2 Development of innovative and novel treatment
3.2 Market Restraints Analysis
3.2.1 Stringent regulatory rules
3.2.2 Unfavorable reimbursement policies
3.3 Covid-19 Market Impact Analysis
4. APAC Parkinson’s Disease Treatment Market Segmentation
4.1 By Drug Class:
4.1.1 Dopamine Receptor Agonists
4.1.2 Mono Amine Oxidase Inhibitors
4.1.3 Carbidopa
4.1.4 Anticholinergics
4.1.5 Other Drug Classes
4.2 By Distribution Channel:
4.2.1 Retail Pharmacies
4.2.2 Hospital Pharmacies
4.2.3 Online Pharmacies
4.3 By Patient Care Setting:
4.3.1 Clinics
4.3.2 Hospitals
4.4 By Country:
4.4.1 India
4.4.2 China
4.4.3 Japan
4.4.4 South Korea
4.4.5 Australia
4.4.6 Indonesia
4.4.7 New Zealand
4.4.8 Rest of APAC
5. APAC Parkinson’s Disease Treatment Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6. Competitive Landscape
6.1 Major Top Market Players
6.2 Products in Pipeline
6.3 R&D Initiatives in Parkinson’s Disease Market
6.4 Notable recent deals in Parkinson’s Disease Market
6.4.1 Joint Ventures
6.4.2 Partnerships
6.4.3 Mergers & Acquisitions
6.4.4 Strategic divestments
7. Key Company Profiles
7.1 Teva Company overview
Product & Services, Strategies & Financials
7.2 GSK Company overview
Product & Services, Strategies & Financials
7.3 AbbVie Company overview
Product & Services, Strategies & Financials
7.4 Novartis AG Company overview
Product & Services, Strategies & Financials
7.5 Merck Company overview
Product & Services, Strategies & Financials
7.6 Sun Pharma Company overview
Product & Services, Strategies & Financials
7.7 UCB Company overview
Product & Services, Strategies & Financials
8. Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
9. Factors Driving Future Growth
9.1 New Trends and Development of Parkinson’s Disease market
9.2 Future Opportunities
10. Strategic Recommendations

APAC Parkinson’s Disease Treatment Market Analysis Segmentation

By Drug Class:

On the basis of drug class, the market is segmented into Carbidopa/Levodopa, Dopamine Receptor Agonists, MAO-inhibitors, Anticholinergics and other drugs. The Carbidopa/Levodopa segment is expected to account for the largest share of the market in 2017. The growth in this segment is primarily attributed to the potency of the drug.

By Distribution Channel:

By distribution channel, the market is segmented into hospital pharmacies, retailer pharmacies, and online pharmacies. In 2017, the hospital pharmacies segment accounted for the largest share of the market. Increasing number of patient visits to the hospital due to the availability of diagnostic laboratories and presence of skilled neurologists are driving the growth of hospital pharmacies segment.

By Patient Care Setting:

On the basis of patient care setting, the Parkinson’s disease treatment market is segmented into hospitals and clinics. In 2017, hospitals are expected to account for the largest share of the market. Robust health infrastructure and presence of skilled neurologists are the driving factors for hospital segment.

By Country:

Emerging economies of the developed and developing countries such as India, China, Japan and others in the Asia Pacific are expected to create lucrative opportunities for the market players in the region during the forecast period.

Research Methodology

Insights10 will provide you reports within 10 key parameters which are:

  1. Market overview
  2. Market growth drivers & restraints
  3. Epidemiology or disease type
  4. Market segmentation
  5. Market share
  6. Competitive landscape
  7. Key company profiles
  8. Healthcare policies & regulatory framework
  9. Reimbursement scenario
  10. Factors driving future growth

Based on our many years of experience, we believe that these are the parameters that are critical to decision making for business stakeholders. Our focused approach to develop reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.

Our analysis methodology involves three critical stages:

Stage I: Market Data Collection

Primary Interviews: We have developed a network of experts, freelancers and researchers across countries through which we engage with local experts to gather key data points and assumptions around each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.

Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain the high level of accuracy and consistency. The market data is analysed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, market share as well as segment-level analysis of the specific market. Our report includes precise, to the point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.

Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:

  • Statistical Databases
  • Company Websites/Annual Reports
  • Trade Publications
  • Online Databases
  • Published Research Reports
  • Whitepapers
  • Press Releases of Key Market Players

Stage II: Market Data Analysis and Statistical Model

Market Trends: We generally look at macro parameter and micro indicators. The macro parameters includes changes in government policies, demand and supply of the market, government intervention programs and major market share. The micro indicators GDP growth, market size, market volume etc. We also understand nuances specific to each country like US, Canada, India, Germany, etc. and have worked across 60+ countries and hence no only understand global trends, but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.

Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. start with large overall market and segment different areas and bottom-up approach i.e. start with population and epidemiology and roll up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.

The top-down approach mainly used for new product forecasting and bottom-up approach is used for demand estimation of any product for different countries summed up to form total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.

The study on the market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and Africa for the period of 2020 to 2028. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape and policy and regulatory scenario and the quantitative analysis covers different market estimates and forecasts.

Data Triangulation & Validation:

Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases and the company level averages etc.

We make sure to finalize the numbers in alignment to the market research. Firstly, our internal experts ensure thorough validation and checking to ensure the accurate and precise analysis and then validation is also done using multiple data analysis model.  Two level validation is done and entails finalization of report scope and to way of representation pattern.

Stage III: Interpretation and Presentation

Analysis & Interpretation: The information gathered is then analysed and synthesized. A second series of interviews are done if necessary to check and validate. The future opportunities are analysed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results are then, interpreted by considering following parameters: (a partial list)

  • Establishing market drivers and trends
  • Analyzing regulatory landscape to understand future growth
  • Market Segment based analysis to obtain revenue / volume
  • Analyzing current needs and determining penetration to estimate market

Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and its impact to the different segments within the market.
Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.

Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumptions.
The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.

To request a free sample copy this report, please complete the form below.

    We value your inquiry and offer free customization with every report to fulfil your exact research needs.

    This website is secure and your personal details are safe.

    This report addresses

    • Market intelligence to enable effective decision making
    • Growth opportunities and trend analysis
    • Competitive benchmarking
    • Historical data & forecasts
    • Regional opportunities

    Need more?

    • Speak to our analyst to know how this research was put together
    • Add more countries or regions as part of customisation
    • Understand how this report can have direct impact on your revenue

    Get a custom report based on your requirements